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Introduction
B- cell chronic lymphocytic leukemia (B- CLL) is the most 
common type of leukemia in Western countries, and the 
majority of patients are >60 years of age at diagnosis 
[1]. Over the last decades, the understanding of B- CLL 
biology has advanced considerably with the discovery of 
alterations in the B- cell signaling transduction pathways 
that contribute to the disease heterogeneity and help pre-
dict its clinical course.
All malignant B- CLL cells share several unique features, 
including the absence of a common molecular abnormality, 
randomly balanced chromosomal translocations, and the 
inability of malignant B- lymphocytes to exist as a trans-
formed cell line [2, 3]. Most intriguingly, however, nearly 
all B- CLL cells express CD5 [4], which is a common T- cell 
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Abstract
The B- cell receptor (BCR) signaling pathway is of great importance for B- cell 
survival and proliferation. The BCR expressed on malignant B- CLL cells con-
tributes to the disease pathogenesis, and its signaling pathway is currently the 
target of several therapeutic strategies. Although various BCR alterations have 
been described in B- CLL at the protein level, the mRNA expression levels of 
tyrosine kinases in B- CLL compared to that in normal CD5- high and CD5- low 
B- lymphocytes remain unknown. In the current study, we measured the mRNA 
expression levels of CD79A, CD79B, LYN, SYK, SHP1, and ZAP70 in purified 
populations of CD5- high B- CLL cells, CD5- low B- cells from the peripheral 
blood of healthy donors, and CD5- high B- cells from human tonsils. Here, we 
report a clear separation in the B- CLL dataset between the ZAP70- high and 
ZAP70- low subgroups. Each subgroup has a unique expression profile of BCR 
signaling components that might reflect the functional status of the BCR signal-
ing pathway. Moreover, the ZAP70-low subgroup does not resemble either CD5- 
high B- lymphocytes from the tonsils or CD5- low lymphocytes from PBMC 
(P < 0.05). We also show that ZAP70 is the only gene that is differentially 
expressed in CD5- high and CD5- low normal B- lymphocytes, confirming the 
key role of Zap- 70 tyrosine kinase in BCR signaling alterations in B- CLL.
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surface antigen, and it remains unclear whether this feature 
is a fingerprint of the normal cellular counterpart or a 
malignancy- related property. After the discovery of the 
CD5- high B- CLL phenotype, Hayakawa et al. [5] demon-
strated the presence of CD5- high B- cells in fetal livers 
and their preferential abundance in young mice. Similarly, 
CD5- high B- cells are more frequently observed in human 
cord blood than in adult peripheral blood [6], and their 
percentage decreases with age. In adult human lymphoid 
tissue, CD5- high B- cells are located in the follicle mantle 
zone and comprise a large subpopulation of tonsillar B- cells. 
In a mouse model, it has recently been shown that a 
subset of CD5- high cells has a potential to give rise to 
B- CLL- like cells in adult animals [7].
Despite the shared pattern of surface antigens, subpopula-
tions of B- CLL cells demonstrate a striking heterogeneity 
in their molecular and functional features. Thus, B- CLL 
cells in the peripheral blood have a genetic profile and 
phenotype that are similar to those of memory B- cells, while 
B- CLL cells in the lymph node and bone marrow exhibit 
the characteristics of activated B- cells with an increased 
proliferative potential [8–10]. At the molecular level, the 
diversity of B- CLL clones, which are known to contribute 
to disease pathogenesis, affect the BCR signaling pathway.
The B- cell receptor is a transmembrane immunoglobulin 
complex that is associated with an Igα (CD79a) and Igβ 
(CD79b) heterodimer. In normal B- cells, tyrosine kinases, 
such as Lyn and Syk, phosphorylate the ITAM motifs in 
the CD79α and CD79β receptor subunits, resulting in the 
downstream activation of BTK, PI3K, and PLCγ and further 
signal propagation [11]. BCR abnormalities in B- CLL cells 
include low to undetectable levels of monoclonal surface 
immunoglobulins, a reduced expression of CD79b, and a 
malfunction in the downstream pathway, which is predi-
cated by the constitutive activation of both the Lyn and 
Syk kinases [12, 13]. The constitutive activation of Lyn 
leads to the phosphorylation of the immunoreceptor tyrosine 
inhibitory motifs (ITIMs) in CD5 inhibitory coreceptors, 
which are aberrantly expressed on B- CLL cells. Thus, CD5 
provides an anchoring site for Src homology 2 domain- 
containing phosphatase 1 (Shp- 1), thereby triggering nega-
tive feedback signaling. In addition, compared to normal 
B- cells, Syk tyrosine kinase has been reported to be over-
expressed in B- CLL cells at both the mRNA and protein 
levels [14]. However, the most obscure feature of B- CLL 
signaling is the expression of Zap- 70 tyrosine kinase in 
malignant lymphocytes. Zap- 70 is normally present in 
T- cells and B- CLL cells and is thought to reflect the BCR 
activation status, which, in turn, correlates with increased 
tumor proliferation and a shorter time to disease progres-
sion [13, 15]. Altogether, these findings implicate the 
antigen- dependent BCR activation as a major pathway of 
B- CLL progression and pathogenesis [16].
Although it is known that Zap- 70 can be expressed in 
a subpopulation of normal CD5- high tonsillar B- cells 
depending on the state of their activation, the BCR status 
and signaling transduction pathways in these unconven-
tional B- lymphocytes remain to be elucidated. In this work, 
we describe for the first time the transcriptional profiles 
of BCR signaling components in CD5- high and CD5- low 
normal B- cells, compare normal B- cells to malignant B- CLL 
lymphocytes, and confirm the role of ZAP70 as a unique 
kinase gene that allows for the distinction among different 
normal and tumor B- cell subpopulations.
Materials and Methods
Samples
The B- CLL specimens were obtained from untreated 
patients undergoing lymphoma diagnosis verification at 
the National Research Centre for Haematology (Moscow) 
or “GeneTechnology” Diagnostic Centre (Moscow). The 
samples were immunophenotyped by flow cytometry for 
each patient. Peripheral blood from healthy donors 
(n = 10) was used for the normal T- and B- lymphocyte 
sorting. Additionally, 10 specimens of nonmalignant tonsils 
from children undergoing routine tonsillectomies were 
obtained from St. Vladimir’s Children Hospital (Moscow, 
Russia). All tissue specimens were evaluated by immuno-
histochemistry; and single cell suspensions were prepared 
using a MediMachine (BD, USA) for the flow cytometry 
and CD5+CD19+ B- cell sorting. All human material was 
obtained with informed consent. All procedures were in 
accordance with the ethical standards of the responsible 
local committee (at the National Research Centre for 
Haematology) and the Helsinki Declaration of 1975 as 
revised in 2008.
Flow cytometry
PBMCs of B- CLL patients and healthy donors were derived 
from whole blood by Ficoll gradient centrifugation. Single 
cell suspensions were prepared from fresh human tonsil 
specimens using a MediMachine (BD, USA) and filtered 
through a 40- μm cell filter. Surface staining was performed 
with the monoclonal antibodies anti- CD5 FITC (clone DK23, 
DAKO, USA), anti- CD19 PE- Cy5 (clone HIB19, eBioscience, 
USA), anti- CD23 PE (clone MHM6, DAKO, USA), FMC7 
FITC (clone MCA792F, Serotec, USA), anti- CD20 PE- Cy5 
(clone 2H7, eBioscience, USA), and anti- κ light Ig chain 
and anti- λ light Ig chain (κ- FITC/λ- PE, AHM4907, Invitrogen, 
USA). The cells were incubated with the antibodies at +4°C 
for 20 min, washed with PBS, and analyzed on a FACSAria 
SORP cell sorter (BD Biosciences, USA). Diva software (BD 
Biosciences, USA) was employed for the data analysis.
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All samples were kept at +4°C during staining and 
prior to FACS analysis. Primary FACS profiles were 
obtained for each specimen on the day of retrieval typi-
cally in 4 h after extraction. Aliquots of cells were frozen 
in FBS with 10% DMSO in liquid nitrogen for further 
FACS sorting.
Cell sorting
Sorting was performed separately on thawed specimens 
using a 5- laser FACSAria SORP instrument (BD Biosciences, 
USA) with a 70- μm nozzle and the corresponding system 
pressure parameters. Over 10,000 cells were sorted in each 
sample. The purity of the sorted populations was assessed 
by flow cytometry and exceeded 98%.
B- CLL cells were stained with anti- CD3- APC- Cy7 (clone 
HIT3a, BioLegend, USA), anti- CD23- APC (EBVCS- 5, 
BioLegend, USA), anti- CD19- FITC (clone HIB19, eBiosci-
ence, USA), anti- CD5- PE- Cy7 (clone UCHT2, BD, USA), 
and anti- CD38- PE or anti- CD38- PE- Cy5 (both HIT2, eBio-
science, USA) antibody combination. Malignant B- CLL cells 
were purified from peripheral blood based on the CD5+/
CD3−/CD19+/CD23+/CD38+ - immunophenotype.
CD5- high normal tonsillar B- lymphocytes were stained 
with anti- CD3- FITC (clone HIT3a, BioLegend, USA), anti- 
CD23- PE (clone EBVCS- 5, BioLegend, USA), anti- CD19- 
PerCP- Cy5.5 (clone HIB19, eBioscience, USA), 
anti- CD5- APC (clone UCHT2, BD, USA), and anti- CD38- 
PE- Cy7 (clone HIT2, eBioscience, USA) antibody com-
bination. Normal CD5- high B- cells with the CD5+/CD3−/
CD19+/CD23−/CD38+ phenotype were purified from 
human tonsil suspensions. To set gate on tonsillar CD5- 
high B- cells, FMO control for CD5 (anti- CD3- FITC (clone 
HIT3a, BioLegend, USA), anti- CD23- PE (clone EBVCS- 5, 
BioLegend, USA), anti- CD19- PerCP- Cy5.5 (clone HIB19, 
eBioscience, USA), and anti- CD38- PE- Cy7 (clone HIT2, 
eBioscience, USA) antibody combination) was used.
Peripheral blood B- and T- cells from healthy donors 
were stained with anti- CD3- FITC (clone HIT3a, 
BioLegend, USA), anti- CD19- PerCP- Cy5.5 (clone HIB19, 
eBioscience, USA), and anti- CD45- PE (clone HI30, 
BioLegend, USA) antibody combination. B- and T- cells 
were sorted according to the CD3−/CD19+/CD45+ and 
CD3+/CD19−/CD45+ phenotypes, respectively. Sorted 
cells were sedimented at 1000g and lysed for RNA extrac-
tion immediately.
Zap- 70 flow cytometry
Three antibody clones against Zap- 70 (SBZAP, 2F3.2, and 
1E7.2) were tested for flow cytometry and Western blot. 
Anti- Zap- 70- PE (SBZAP) was further used for flow cytom-
etry. Cells were fixed with 1% paraformaldehyde (Merck, 
Germany) for 5 min, washed once with PBS, and per-
meabilized with 1X Perm II reagent (BD, USA) according 
to the manufacturer’s instructions. The staining panel 
included either anti- CD3- FITC (clone HIT3a, BioLegend), 
anti- Zap- 70- PE (clone SBZAP, Beckman Coulter) and 
anti- CD22- APC (clone S- HCL- 1, BD), or anti- CD3- PE- Cy7 
(clone UCHT1, BioLegend), anti- CD19- FITC (clone 
HIB19, eBioscience), anti- Zap- 70- PE (clone SBZAP, 
Beckman Coulter), and anti- CD22- APC (clone S- HCL- 1, 
BD).
RNA and cDNA
RNA was extracted from thawed suspensions of the sorted 
and unsorted cells using the RNeasy Mini Kit (Qiagen, 
USA) according to the manufacturer’s instructions. The 
RNA concentration was measured using a NanoPhotometer 
(Implen, Germany), and its purity was assessed according 
to the A260/A280 and A260/A230 ratios. cDNA was tran-
scribed using the ImProm- II AMV- Reverse Transcription 
Kit (Promega, USA) according to the manufacturer’s 
instructions.
Primers and real- time PCR
Real- time qPCR was further performed on Quantica 
(Barlow Scientific, UK) and StepOne (Applied Biosystems, 
USA) cyclers using Taq- polymerase in SYBR Green I buffer 
(Syntol, Russia). The reaction protocol included denatura-
tion (95°C, 10 min), followed by 40 amplification cycles 
(95°C, 15 sec; 60°C, 30 sec; and 72°C, 60 sec). All samples 
were processed in triplicate. All primers were synthesized 
and HPLC- purified by Syntol (Russia). A control cDNA 
sample was included in each PCR run and served as an 
inter- run calibrator (IRC) to standardize the data. The 
primer sequences are listed in Table S2.
Data normalization
qPCR data were normalized according to the method 
proposed by Vandesompele et al. [17]. The following three 
reference genes were used for the normalization: YWHAZ, 
UBC, and HPRT1. In short, the relative expression value 
of each gene of interest was divided by the geometric 
mean of the reference genes’ relative expression values. 
Three suitable reference genes were established previously 
[18] and used in the current work.
Western blotting
Cells were lyzed in RIPA buffer (50 mmol/L Tris- HCl 
pH 7.4, 1% NP- 40, 0.1% SDS, 150 mmol/L NaCl, 1 mmol/L 
EDTA, 0.5% sodium deoxycholate, protein inhibitor 
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cocktail [Roche], and 2 mmol/L PMSF) for 30 min on 
ice. Protein concentration was measured using Bradford 
reagent (Sigma, USA). Thirty μg of protein lysates were 
resolved in 12% SDS- PAGE gel and transferred to 0.2 μm 
nitrocellulose membrane (GE Healthcare, USA), blocked 
with 5% nonfat dry milk, 1X TBS, 0.1% Tween- 20 for 
40 min at RT. Membranes were incubated with primary 
antibodies against Syk (clone Syk- 01, Abcam, UK), Lyn 
(clone Lyn- 01, Abcam, UK), SHP1 (clone EPR5519, Abcam, 
UK), Zap70 (clone 2F3.2, Invitrogen, USA), and Histone- 3 
(Cell Signaling) at +4°C overnight in 1% BSA in 1X TBS, 
0.1% Tween- 20. After washing membranes were incubated 
with secondary antibodies linked with mouse or rabbit 
horseradish peroxidase (Cell Signaling, USA) for 1 h at 
RT. Membranes were washed again, and the proteins were 
visualized using Image Quant LAS 4000 system (GE 
Healthcare, USA).
Statistical analysis
The statistical analysis and data plotting were performed 
using GraphPad Prism (GraphPad Software, version 5, 
San Diego, CA, USA). The differences in the mRNA 
expression levels between groups of malignant and normal 
lymphocytes were considered significant based on a non-
parametric Mann–Whitney test with Bonferroni correction 
for multiple testing.
Results
Purification of normal lymphocytes from 
tonsils
Nonmalignant CD5- high B- cells with the CD5+/CD19+/
CD23- low−/CD38+ phenotype were purified by FACS from 
human tonsils (n = 10) and comprised 3–10% B- lymphocytes. 
The normal B- (n = 10) and T- cell (n = 10) samples were 
sorted from healthy donor peripheral blood based on the 
CD19+/CD45+ and CD3+/CD45+ phenotypes, respectively. 
The sorting strategy for the minor normal population of 
CD5+/CD19+ tonsillar B- cells is presented in Figure 1.
All sorted populations were reanalyzed by flow cytometry 
to confirm a purity >98%, and 104–105 cells were col-
lected from each sample. All samples had a similar CD5- 
low/CD19+ phenotype. Unlike the B- CLL lymphocytes, 
these cells did not express CD23, CD43, CD25, or CD27 
on their surface.
Cell sorting of B- CLL samples is a 
prerequisite for a gene expression analysis
The differential diagnosis of B- CLL was established accord-
ing to the WHO classification as follows: the clonality 
of the neoplastic lymphocytes was confirmed by both 
surface and intracellular kappa/lambda immunoglobulin 
light chain expression, and all cells had the following 
Figure 1. Flow cytometry and sorting strategy for CD5+ B- cells from human tonsils. The upper panel presents the sorting gates. “Cells” are gated 
from debris according to forward and side light scatter characteristics; “singlets” are gated according to FSC signal width/height ratio; “B- cells” are 
gated based on CD19 fluorescence; a subpopulation of B- cells (“CD5+ B- cells”) with a moderate CD5+ staining level; the gating is sequential. To gate 
on the subpopulation of “CD5+ B- cells” correctly FMO control was used (see Materials and Methods). CD5 median fluorescence values (MFI) for 
different lymphocyte populations are as follows: MFI(CD5) T- cells = 9462, MFI(CD5) B- cells(general) = 405, MFI(CD5)CD5+B- cells = 1939. The lower 
panel expands on CD5+ B- cell phenotype: unlike B- CLL the cells of interest are CD23- low, CD27- low, CD25- low, and universally CD38+.
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characteristic surface phenotype: CD19+/CD5+/CD23+/
CD20- low+/CD22- low+/CD43+/CD103−/CD11c− (Fig. 
S1).
The CD38 expression level in the B- CLL lympho-
cytes varied substantially; however, the majority of 
the cases were CD38- negative (the data regarding the 
population percentages and CD38 levels are summa-
rized in Table S1). B- CLL cells were sorted from 
PBMC samples (n = 20) according to the CD3−/
CD5+/CD19+/CD23+ immunophenotype. An example 
of the sorting strategy of the B- CLL population is 
presented in Figure 2.
In order to assess whether the sorting procedure changed 
the mRNA expression levels of the major signaling BCR- 
associated proteins, 26 unsorted B- CLL specimens were 
compared to 20 sorted B- CLL specimens (Fig. 3). The 
differences in the mRNA expression levels between the 
sorted and unsorted samples were statistically significant 
for ZAP70 (P < 0.0001), LYN (P < 0.0001), and SHP1 
(P < 0.001), but not for SYK. The most obvious differ-
ence was observed in ZAP70 as its mRNA expression 
level decreased by two orders of magnitude in the sorted 
B- CLL group (median 0.047 in sorted B- CLL vs. 1.481 
in unsorted B- CLL, P < 0.001), which is very important 
considering its prognostic value. In the purified B- CLL 
subpopulation, the mRNA expression levels of SHP1 and 
LYN were decreased, and the expression levels of CD79A 
and CD79B were elevated (both 10- fold) compared to 
the levels in the unsorted samples. Altogether, these obser-
vations highlight the problem of sample heterogeneity in 
mRNA expression measurements. While constitutive B- cell 
mRNAs (such as CD79A, CD79B, and SYK) exhibit similar 
or decreased expression levels when normalized to house-
keeping genes in the unsorted samples, the expression 
levels of other mRNAs (ZAP70, SHP1, and LYN) may be 
biased and, thus, “upregulated” due to the presence of 
T- cells in the unsorted samples. Here, we demonstrate 
the statistical error that is introduced by sample 
heterogeneity.
Then, the mRNA expression levels of signal molecules 
in the sorted normal T- cells, different populations of nor-
mal B- cells, and malignant B- CLL lymphocytes were 
assessed.
Expression of signal molecules in normal 
T- cells
T- cells have the lowest mRNA expression levels of LYN 
(median 0.01), SYK (median 0.06), CD79A (median 0.13), 
and CD79B (median 0.37) (Table 1, Fig. 4). Because Zap- 
70 tyrosine kinase is a normal counterpart of the T- cell 
receptor, ZAP70 was upregulated in the T- cells compared 
to all other groups (median 1.3). Simultaneously, we 
observed lower levels of SHP1 (P < 0.05) mRNA, even 
though it is a conventional tyrosine phosphatase that 
blocks downstream TCR signaling.
Figure 2. Flow cytometry and cell sorting strategy for B- CLL cells. “Cells” are gated from debris according to forward and side light scatter 
characteristics; “singlets” are gated according to the FSC signal width/height ratio; “B- cells” are gated based on CD19 fluorescence; B- CLL cells are 
further gated based on the CD3- CD19+CD5+CD23+ cell phenotype; the gating is sequential. The lower panel presents three different cases of B- CLL 
with varying densities of surface CD38 (identified as high+, low [med], and low−).
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Expression of B- cell receptor components in 
CD5- high and CD5- low normal B- cells
One of the aims of our study was to describe the expres-
sion profiles of the BCR signaling components in non-
malignant CD5- high B- cells and compare these profiles 
to those of normal B- cells from peripheral blood. The 
expression level of SYK mRNA in the CD5- high B- cells 
from human tonsils was similar to that in the normal 
CD5- low B- cells (Table 1), although the variation coef-
ficient in this group was several fold higher (CV = 31.7% 
for CD5- low B- cells vs. 119.4% for CD5- high B- cells). 
The differences in the mRNA expression levels of all other 
genes, except for ZAP70, in the CD5- high and CD5- low 
B- cells were statistically insignificant. The expression of 
ZAP70 in the CD5- high B- cells was more than 10- fold 
higher than that in the CD5- low B- lymphocytes (median 
1.3 vs. 0.08, respectively, P = 0.04). Fifteen samples of 
human tonsils were immunofluorescently stained for intra-
cellular Zap- 70, and eight samples contained Zap- 70- 
positive B- cells (data not shown).
Figure 3. mRNA expression level of BCR signaling components in sorted and unsorted B- CLL cells. Each measurement is performed in triplicate, and 
cDNA is normalized against the following three genes: YWHAZ, HPRT1, and UBC; bars represent the medians of each group.
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Expression of signal molecules in sorted 
B- CLL lymphocytes
CD79A was expressed at nearly the same level (range 
4.83–11.04) in all types of B- cells, including the malignant 
B- CLL lymphocytes. As expected, the mRNA levels of 
CD79B and SYK in the B- CLL group was compared to 
that in the normal CD5- high and CD5- low B- cells 
(P < 0.05, see Table 1). SHP1 mRNA was decreased in 
the B- CLL samples to the same extent as that in the 
T- cells compared to that in the normal B- cells. The range 
of the expression of ZAP70 in the B- CLL group varied 
dramatically – from 1 × 10−5 to 0.78 (median 0.07, 
Table 2). Interestingly, a clear division of the B- CLL group 
into ZAP70- high and ZAP70- low subgroups (Fig. 4) was 
observed.
Thus, we separated the ZAP70- low (below 0.02) and 
ZAP70- high (range 0.07–0.78) subgroups and compared 
their levels of mRNAs (Table 2). In the B- CLL ZAP70- 
low subgroup, a statistically significant downregulation of 
SYK, SHP1, and CD79B, and an upregulation of CD79A 
mRNA levels (P < 0.05 for all datasets) were observed. 
Thus, the ZAP70- high and ZAP70- low subgroups of B- CLL 
have different transcription profiles for all BCR signaling 
molecules, except for LYN tyrosine kinase gene, which 
tends to be downregulated in all B- CLL lymphocytes 
compared to normal CD5- high and CD5- low B- cells. The 
ZAP70- low subgroup appears to have a unique expression 
profile because it does not resemble either the CD5- high 
B- lymphocytes from the tonsils or the CD5- low lympho-
cytes from the peripheral blood (the differences were 
statistically significant for all mRNAs, except for CD79A).
Differences in protein expression of signal 
tyrosine kinases in sorted B- CLL cells
Finally, we have tested whether differences in mRNA 
expression can be confirmed on protein level and analyzed 
protein expression of BCR tyrosine kinases in ZAP70-high 
and ZAP70- low B- CLL subsets compared to T- cells as a 
control. In ZAP70- low group, we confirmed a significant 
downregulation of Zap- 70 protein both by flow cytometry 
and immunoblotting. We also confirmed the downregula-
tion of Syk tyrosine kinase for ZAP70- low group on a 
protein level, and no differences in Lyn expression, the 
only discordance in transcriptional and translational levels 
was for SHP- 1 phosphatase that was uniformly expressed 
in all tested groups (Fig. 5).
Discussion
FACS purification of cell populations for further qPCR 
analysis provides a powerful combination of methods that 
allows for gene expression profiling of both cancer cells 
and cancer- associated cells. In this study, FACS sorting 
was performed to evaluate the quality of the B- CLL gene 
expression data. We revealed statistically significant dif-
ferences in the mRNAs of the BCR components in the 
sorted and unsorted B- CLL samples, except for SYK tyrosine 
kinase. Thus, comparisons of unsorted B- CLL samples 
and sorted normal B- cells can be incorrect in signal trans-
duction pathways’ studies because the admixture of T- cells 
can alter the quantity of the tyrosine kinase cDNA. Using 
the FACS sorting method, we isolated the nonmalignant 
CD5- high B- cells and, for the first time, described the 
transcriptional profile of the BCR components.
CD5- high normal B- cells were first described in the 
fetal spleen, where they comprised 40–60% of the splenic 
B- cells, but were infrequent in the adult spleen and fetal 
liver [19]. In adult tonsils, CD5- high B- cells bear CD23 
(low), IgM, and IgD [20]. These B- cells seed in the mantle 
zone of the lymphoid follicles, respond to polyclonal acti-
vation, have unmutated V- kappa genes, and are not capable 
of producing natural polyspecific antibodies [21–23]. It 
was shown that Zap- 70 was present in normal CD5- high 
B- cells from human tonsils but not in B- cells from periph-
eral blood [24]. Here, we show that CD5- high and CD5- 
low B- cells have similar mRNA expression levels of SYK, 
LYN, CD79A, CD79B, and SHP1 and confirm that ZAP70 
is the only upstream tyrosine kinase gene that allows for 
the discrimination among these cells based on the mRNA 
level.
Table 1. mRNA expression levels of B- cell receptor components in normal and malignant lymphocytes.
Lyn SHP1 Syk ZAP70 CD79a CD79b
B- CLL 0.05–1.84 0.01–4.63 0.08–5.79 0.002–0.78 0.25–21.40 0.19–12.97
Median 0.24 0.53 0.68 0.07 5.22 1.15
B- cells 0.35–3.49 0.33–3.56 5.32–12.97 0.02–0.68 2.50–43.76 2.47–31.57
Median 0.68 2.17 7.03 0.08 9.63 19.18
CD5+ B- cells 0.60–17.28 0.61–14.00 1.80–26.81 0.06–0.45 2.90–30.00 6.50–84.25
Median 2.62 2.81 3.12 0.22 11.04 55.72
T- cells 0–0.09 0.24–2.70 0.02–0.91 0.66–2.42 0.03–0.85 0.17–9.10
Median 0.01 0.91 0.06 1.3 0.13 0.37
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The Zap- 70 protein is a 70- kDa member of the Syk 
family of protein tyrosine kinases and was first identified 
as a crucial element for the downstream signaling from 
the T- cell receptor [25]. Similarly to Syk tyrosine kinase 
after B- cell receptor (BCR) engagement, Zap- 70 is recruited 
to the phosphorylated immunoreceptor tyrosine activation 
motifs of the CD3 chains that are present in the T- cell 
receptor, where it subsequently becomes phosphorylated 
and initiates several signaling cascades [26]. The expression 
of the Zap- 70 protein and its correlation with the adverse 
prognosis in certain subsets of B- lymphocyte- derived malig-
nancies prompted the analysis of its functions in a 
B- lymphocyte setting. In B- lymphocytes, Zap- 70 binds to 
the parts of the heterodimer CD79a/CD79b [27] and delays 
Figure 4. mRNA expression level of BCR components in normal and malignant lymphocytes. Each measurement is performed in triplicate, and cDNA 
is normalized against the following three genes: YWHAZ, HPRT1, and UBC.
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BCR internalization after IgM stimulation [28]. In 2003, 
Weistner et al. found that Zap- 70 expression was a valu-
able prognostic marker in B- CLL and that its expression 
is mainly correlated with known prognostic factors, such 
as the IGHV mutation status and percentage of CD38- 
positive B- cells [29]. The low levels of Zap- 70 corresponded 
to indolent B- CLL, and high Zap- 70 levels corresponded 
to a more aggressive disease or disease progression. Further 
studies confirmed the predictive value of this marker 
[30–32]; however, the flow cytometry measurement of the 
Zap- 70 status is often inaccurate because of small differ-
ences between positive and negative populations [33] that 
can also be affected by the choice of antibody clone and 
gating procedures [34]. Consequently, mRNA quantification 
for the determination of ZAP70 expression was proposed 
[35]. There were several attempts to measure ZAP70 mRNA 
expression in normal and malignant tissues [36–39]. In 
those studies, the aim was to determine the correlation 
between ZAP70 expression and other predictors of a pure 
outcome, such as the IGHV mutation status and CD38 
expression. To normalize the ZAP70 mRNA expression 
levels in tumor lymphocytes, GUS, GAPDH, and PP1A 
were proposed; however, each of these genes was used as 
a sole reference gene. To date, there are no studies includ-
ing several housekeeping genes simultaneously for the 
accurate normalization of the ZAP70 mRNA level. The 
Table 2. mRNA expression levels of signaling molecules in the ZAP70- low and ZAP70- high subgroups in the B- CLL dataset.
ZAP- 70 Lyn Syk SHP- 1 CD79a CD79b
B- CLL ZAP- 70 
“high”
0.07–0.78 0.05–0.90 0.42–5.79 0.24–4.63 2.74–16.30 0.26–9.56
Median 0.31 0.20 2.25 1.57 4.83 2.57
B- CLL ZAP- 70 
“low”
0.002–0.02 0.05–1.84 0.08–0.63 0.15–0.53 4.87–21.40 0.25–1.15
Median 0.01 0.18 0.27 0.25 7.23 0.70
Figure 5. Protein expression level of BCR components in B- CLL ZAP70- high and ZAP70- low representative cases. (A) Immunoblotting of signaling 
tyrosine kinases in ZAP70- low sample (sample 1) and ZAP70- high sample (sample 2), histone H3 was taken as a technical control. (B) Sample 1 (see 
A) analyzed by flow cytometry. Median fluorescence intensities of Zap70 in B- CLL and T- cell populations differ ×2.85- fold; MFI(Zap70)T- cells/MFI(Zap70)
B- CLL = 2.85. (C) Sample 2 (see A) analyzed by flow cytometry. Median fluorescence intensities of Zap70 in B- CLL and T- cell populations do not differ. 
MFI(Zap70)T- cells/MFI(Zap70)B- CLL = 1.
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best single- gene SD- based approach assumes that the gene 
expression levels are normally distributed throughout the 
sample set [40]; however, the normality of the distribution 
in a dataset is rarely addressed in clinical studies. Accurate 
normalization with several reference genes increases the 
method’s resolution and allows for resolving groups with 
only a 10- fold difference in gene expression level as dem-
onstrated in our previous work [18, 41]. In current study, 
we used three housekeeping genes, namely, YWHAZ, UBC, 
and HPRT1, that have been shown to be optimal for PCR 
data normalization in different types of lymphoid tissue 
[18], Regarding ZAP70 expression, the B- CLL samples in 
our dataset can be divided into the following two groups 
(Table 2): low ZAP70 mRNA expression (8 samples, nor-
malized cDNA quantity lower than 0.04, median 0.01) 
and high ZAP70 mRNA expression (12 samples, normalized 
cDNA quantity higher than 0.15, median 0.31). The ZAP70 
mRNA level in the first group corresponds to that in the 
CD5- low normal B- cells, and the ZAP70 mRNA level in 
the second group corresponds to that in the CD5- high 
B- cells from the tonsils.
Overall, in the ZAP70- low group, we observed a 
downregulated mRNA expression of SYK, CD79B, and 
SHP1 compared to that in the ZAP70- high group. 
Moreover, the ZAP70-low B- CLL cells demonstrated a 
lower mRNA expression of SHP1, CD79B, SYK, and 
LYN compared to the normal CD5- high and CD5- low 
B- cells (P < 0.05 for all groups), thus demonstrating a 
unique mRNA profile that differs from any other type 
of B- cells. This is the first report of the downregulation 
of a signal tyrosine kinase at the mRNA level. In 2009, 
Buchner et al. [14] showed an elevated mRNA expres-
sion level of SYK tyrosine kinase in B- CLL cells, but 
these authors used the β- glucuronidase gene as the sole 
reference gene in the ΔΔCt method, making their results 
questionable since nothing is known about the expres-
sion stability of this gene in normal and malignant 
lymphoid tissue.
Most of the recent BCR studies in B- CLL cells focused 
on measuring the protein expression and phosphorylation 
level of these molecules, namely, Lyn and Syk kinases, 
which were reported to be constitutively active and upregu-
lated at the protein level [12, 42]. While Contri et al. 
[12] showed that Lyn is overexpressed at protein level, 
they reported no differences in mRNA expression of LYN 
measured by RT qPCR (data were not shown). Gobessi 
et al. [13] reported the substantial quantities of Y352- 
phosphorylated SYK in most of B- CLL samples, but there 
were no data on the overall quantity of SYK protein in 
B- CLL cells compared to normal B- lymphocytes. To date, 
there are no studies that directly compare mRNA and 
protein expression of BCR tyrosine kinases in B- CLL cells 
and all the clinical studies that investigate the impact of 
BCR signaling pathway alterations in overall survival and 
Figure 6. A model of BCR signaling pathways in normal B- cells and CLL lymphocytes. (A) Structure of B- cell receptor in normal B- cells, characteristic 
features of BCR in CD5- positive B- cells are highlighted in red; (B) upregulation of key tyrosine kinases in B- CLL cells with high level of ZAP70 
expression leads to activation of major survival pathways; (C) downregulation of tyrosine kinases in CLL cells with low level of ZAP70 expression leads 
to signal truncation, which implies the existence of alternative signaling pathways that eventually promote proliferation.
A
B C
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clinical prognosis measure mRNA expression without 
confirmation of alterations at protein level [43]. The pos-
sible reason is the difference in the detection limit of 
real- time PCR as a semiquantitave method compared to 
qualitative measurement of protein expression by Western 
blotting.
The only exception is Zap- 70 molecule, that is routinely 
measured both on protein and mRNA levels with flow 
cytometry and real- time PCR, respectively. For instance, 
assessing the samples from E2997 multicenter phase III 
trial, Kaplan et al. [44] showed that B- CLL samples can 
be clearly distinguished into two subpopulations based on 
ZAP70 expression. They have also showed that ZAP70- high 
group samples demonstrate higher levels of antiapoptotic 
proteins (Bcl- 2, Puma, survivin), which is in line with 
our hypothesis on the defective apoptosis as a main result 
of BCR hyperactivation. Using high- resolution immunophe-
notyping technology, this group also reported that increased 
expression of ZAP70 is correlated with low phosphorylation 
levels of Syk and Zap- 70 and that more aggressive clinical 
course of B- CLL is related to higher levels of Zap- 70 more 
than BCR activation pathway [45], thus justifying the 
importance of functional measurements of tyrosine kinases 
both in fundamental and clinical research.
We have observed two distinct groups of B- CLLs based 
on differential ZAP70 mRNA expression. However, none 
of these groups fully correspond to any of the observed 
normal B- cell populations in terms of investigated mRNA 
expression profiles. For instance, ZAP70- low B- CLLs 
have similarly decreased mRNAs of SYK and other BCR- 
associated molecules. Such generally “low- expressing” 
profile is highly uncommon for normal B lymphocytes 
and may correspond to “signaling- deficient” B- CLL cases, 
cited in literature previously [46]. At the same time, 
ZAP70- high B- CLLs do not exhibit such obvious abnor-
malities but differ from normal B- cells in expression 
of CD79B (which is common for all CLL samples) 
together with differences in SYK and LYN mRNA, which 
expression is similar to CD5- high B- cells and slightly 
downregulated compared to normal CD5- low 
B- lymphocytes. In our research, we have also confirmed 
the downregulation of Syk tyrosine kinase in ZAP70- low 
group, and for the first time describe the correlation 
between the mRNA and protein expression of signaling 
tyrosine kinases in different subsets of B- CLL samples, 
however, a quantitative measurement of phosphorylation 
pattern of signaling tyrosine kinases as a hallmark of 
their functionality is an important issue for further 
investigation.
Thus, in the ZAP70- low group, we observed BCR sign-
aling incompetence, which suggests that other mechanisms 
may override the inhibition of the B- cell receptor pathway 
and eventually promote B- cell proliferation. The evidence 
supporting this hypothesis is that a subset of B- CLL cells 
with unresponsiveness to sIg ligation display constitutively 
activated extracellular signal- regulated kinase ERK1/2 in 
the absence of Akt activation and the presence of increased 
NFAT transactivation [47]. In contrast, the ZAP70- high 
group displays an overexpression of all kinases involved 
in BCR signalosome formation together with the down-
regulation of SHP1 inhibiting phosphatase gene (Fig. 6), 
which leads to the activation of the NFkB and AKT sur-
vival pathways and the expression of antiapoptotic proteins, 
such as mcl- 1 and bcl- 2, which have been shown to act 
as crucial players in defective apoptosis in B- CLL cells 
[48, 49]. Altogether, these data are relevant for differential 
therapeutic strategies and suggest a new approach of select-
ing therapeutic kinase inhibitors for the two B- CLL subsets 
that could be easily distinguished by the ZAP70 mRNA 
expression.
In conclusion, our observations suggest that it is neces-
sary to perform a cell sorting prior to an analysis of gene 
expression to provide new insight into the regulation of 
the transcriptional levels of PTKs of B- cell receptor in 
different B- CLL subsets with high and low ZAP70 expres-
sion. Our data are consistent with a model in which 
Zap- 70 is a key regulatory molecule, and its expression 
allows for the discrimination among different types of 
normal and malignant lymphocytes.
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